EP0617621A4 - Antagonistes de la cholecystokinine centrale possedant une efficacite pharmaceutique. - Google Patents

Antagonistes de la cholecystokinine centrale possedant une efficacite pharmaceutique.

Info

Publication number
EP0617621A4
EP0617621A4 EP92903432A EP92903432A EP0617621A4 EP 0617621 A4 EP0617621 A4 EP 0617621A4 EP 92903432 A EP92903432 A EP 92903432A EP 92903432 A EP92903432 A EP 92903432A EP 0617621 A4 EP0617621 A4 EP 0617621A4
Authority
EP
European Patent Office
Prior art keywords
pharmaceutical effectiveness
cholecystokinin antagonists
central
central cholecystokinin
antagonists
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP92903432A
Other languages
German (de)
English (en)
Other versions
EP0617621A1 (fr
Inventor
David Christopher Horwell
John Hughes
Geoff Neil Woodruff
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Organon Pharma UK Ltd
Original Assignee
Merck Sharp and Dohme Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Sharp and Dohme Ltd filed Critical Merck Sharp and Dohme Ltd
Priority to EP96200242A priority Critical patent/EP0729752A2/fr
Publication of EP0617621A1 publication Critical patent/EP0617621A1/fr
Publication of EP0617621A4 publication Critical patent/EP0617621A4/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D231/00Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/06Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D231/08Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with oxygen or sulfur atoms directly attached to ring carbon atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/195Carboxylic acids, e.g. valproic acid having an amino group
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4151,2-Diazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/20Hypnotics; Sedatives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Anesthesiology (AREA)
  • Addiction (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
EP92903432A 1991-12-20 1991-12-20 Antagonistes de la cholecystokinine centrale possedant une efficacite pharmaceutique. Withdrawn EP0617621A4 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP96200242A EP0729752A2 (fr) 1991-12-20 1991-12-20 Antagonistes centraux de la cholecystokinine possédant une activité pharmaceutique

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US1991/009555 WO1993012791A1 (fr) 1991-12-20 1991-12-20 Antagonistes de la cholecystokinine centrale possedant une efficacite pharmaceutique

Related Child Applications (1)

Application Number Title Priority Date Filing Date
EP96200242A Division EP0729752A2 (fr) 1991-12-20 1991-12-20 Antagonistes centraux de la cholecystokinine possédant une activité pharmaceutique

Publications (2)

Publication Number Publication Date
EP0617621A1 EP0617621A1 (fr) 1994-10-05
EP0617621A4 true EP0617621A4 (fr) 1995-04-05

Family

ID=22226062

Family Applications (1)

Application Number Title Priority Date Filing Date
EP92903432A Withdrawn EP0617621A4 (fr) 1991-12-20 1991-12-20 Antagonistes de la cholecystokinine centrale possedant une efficacite pharmaceutique.

Country Status (3)

Country Link
EP (1) EP0617621A4 (fr)
JP (1) JPH07507993A (fr)
WO (1) WO1993012791A1 (fr)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK0652871T3 (da) * 1992-07-29 2001-12-03 Merck Sharp & Dohme Absorberende artikel med fastgøringssystem, der tilvejebringer dynamisk tilpasning af elasticeret linning
FR2744363B1 (fr) * 1996-02-07 1998-02-27 Rhone Poulenc Rorer Sa Application de derives de thiazolidine a la preparation de medicaments destines au traitement de l'abus de drogues ou de substances donnant lieu a des pharmacomanies ou a un usage excessif
FR2744361B1 (fr) * 1996-02-07 1998-02-27 Rhone Poulenc Rorer Sa Application de derives de pyrrolidine a la preparation de medicaments destines au traitement de l'abus de drogues ou de substances donnant lieu a des pharmacomanies ou a un usage excessif
FR2744362B1 (fr) * 1996-02-07 1998-02-27 Rhone Poulenc Rorer Sa Application de derives de pyrrolidine a la preparation de medicaments destines au traitement de l'abus de drogues ou de substances donnant lieu a des pharmacomanies ou a un usage excessif
TW442449B (en) 1996-07-04 2001-06-23 Hoechst Ag Process for preparing 1,2-dichloroethane by direct chlorination
EP1183242A2 (fr) 1999-05-26 2002-03-06 Du Pont Pharmaceuticals Company Inhibiteurs de transcriptase inverse du vih a base de 1,4-benzodiazepin-2-ones
ES2319074B1 (es) * 2005-07-15 2009-12-03 Laboratorios Del Dr. Esteve, S.A. Combinacion de principios activos.
EP1749525A1 (fr) * 2005-07-15 2007-02-07 Laboratorios Del Dr. Esteve, S.A. Combination de pyrazoline substitués et de médicaments contre la dépendance
US8247438B2 (en) 2008-02-27 2012-08-21 Neuropill, Inc. Methods for treating schizophrenia
US9249161B2 (en) 2010-12-02 2016-02-02 Constellation Pharmaceuticals, Inc. Bromodomain inhibitors and uses thereof
AR084070A1 (es) 2010-12-02 2013-04-17 Constellation Pharmaceuticals Inc Inhibidores del bromodominio y usos de los mismos
EP2705039B1 (fr) 2011-05-04 2017-07-26 Constellation Pharmaceuticals, Inc. Inhibiteurs de bromodomaines et leurs utilisations
US9328117B2 (en) 2011-06-17 2016-05-03 Constellation Pharmaceuticals, Inc. Bromodomain inhibitors and uses thereof
US9624244B2 (en) 2012-06-06 2017-04-18 Constellation Pharmaceuticals, Inc. Benzo [B] isoxazoloazepine bromodomain inhibitors and uses thereof
TWI602820B (zh) 2012-06-06 2017-10-21 星宿藥物公司 溴域抑制劑及其用途
PL3157928T3 (pl) 2014-06-20 2019-07-31 Constellation Pharmaceuticals, Inc. Krystaliczne postacie 2-((4S)-6-(4-chlorofenylo)-1-metylo-4H-benzo[ c]izoksazolo-[4,5-e]azepin-4-ylo)acetamidu

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0411668A2 (fr) * 1989-08-04 1991-02-06 MERCK SHARP & DOHME LTD. Antagonistes centraux de cholécystokinin pour le traitement des troubles psychiatriques

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3663771A (en) * 1971-01-12 1972-05-16 Gulf & Western Industries Distributor rotor with improved contact securing means
IE57892B1 (en) * 1984-06-25 1993-05-05 Rotta Research Lab Glutamic and aspartic acid derivatives
US4820834A (en) * 1984-06-26 1989-04-11 Merck & Co., Inc. Benzodiazepine analogs
IT1215169B (it) * 1985-12-17 1990-01-31 Rotta Research Lab Derivati alchil ossigenati degli acidi glutammico ed aspartico ad attivita antagonista su polipeptidi bioattivi e procedimento per la loro preparazione
CA2032226A1 (fr) * 1989-12-18 1991-06-19 Mark G. Bock Analogues de la benzodiazepine
CA2032427A1 (fr) * 1989-12-18 1991-06-19 Mark G. Bock Analogues de benzodiazepines

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0411668A2 (fr) * 1989-08-04 1991-02-06 MERCK SHARP & DOHME LTD. Antagonistes centraux de cholécystokinin pour le traitement des troubles psychiatriques

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of WO9312791A1 *

Also Published As

Publication number Publication date
EP0617621A1 (fr) 1994-10-05
JPH07507993A (ja) 1995-09-07
WO1993012791A1 (fr) 1993-07-08

Similar Documents

Publication Publication Date Title
FI922958A0 (fi) Farmaceutisk sammansaettning.
FI921060A0 (fi) Farmaceutiska aerosolformuleringar.
FI922316A0 (fi) Farmaceutisk sammansaettning.
FI922252A0 (fi) Farmaceutisk sammansaettning.
FI923581A0 (fi) Farmaceutisk kombinationsformation.
MX9102473A (es) Agentes farmaceuticos.
FI922364L (fi) Farmaceutiska kompositioner.
IT8921891A0 (it) Sistema di scarica.
FI901102A0 (fi) Farmaceutiska kompositioner.
MX9102421A (es) Sistema para montaje de recipiente distribuidor.
FI924405A0 (fi) Lhrh-antagonister.
IT8920486A0 (it) Composizioni farmaceutiche.
DZ1559A1 (fr) Compositions pharmaceutiques.
NO903241D0 (no) Sleideventil.
DE59202784D1 (de) Drehmeldesystem.
NO891130L (no) Doseringspumpesystem.
IT1230308B (it) Sistema stampante modulare.
FI943513A7 (fi) Kolekystokiniiniantagonisteina käyttökelpoisia 3-fenyyliureidoatsepin- 2-oneja ja -bentsatsepin-2-oneja
DE69012258D1 (de) Barriere des Kondensatortyps.
FI921785A0 (fi) Farmaceutisk foerening.
FI921786A0 (fi) Farmaceutisk foerening.
TR199601018A1 (tr) Farmasötik bilesikler.
FI905709A7 (fi) Torkparti i en maskin foer tillverkning av en kontinuerlig bana.
FR2683454B1 (fr) Composition pharmaceutique bactericide.
ES1020808Y (es) Sistema de inodoro.

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19940609

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IT LI LU MC NL SE

A4 Supplementary search report drawn up and despatched

Effective date: 19950210

AK Designated contracting states

Kind code of ref document: A4

Designated state(s): AT BE CH DE DK ES FR GB GR IT LI LU MC NL SE

17Q First examination report despatched

Effective date: 19980630

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 19981111